Mitsonis C, Voussoura E, Dimopoulos N, Psarra V, Kararizou E, Latzouraki E, et al. Factors associated with caregiver psychological distress in chronic schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2012;47:331–7. https://doi.org/10.1007/s00127-010-0325-9.
Article
PubMed
Google Scholar
Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. https://doi.org/10.1038/nrdp.2015.67.
Article
PubMed
Google Scholar
Lindenmayer J-P, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70:990–6. https://doi.org/10.4088/JCP.08m04221.
Article
CAS
PubMed
Google Scholar
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216–26. https://doi.org/10.1002/wps.20060.
Article
PubMed
PubMed Central
Google Scholar
Szkultecka-Dębek M, Miernik K, Stelmachowski J, Jakovljević M, Jukić V, Aadamsoo K, et al. Schizophrenia causes significant burden to patients’ and caregivers’ lives. Psychiatr Danub. 2016;28:104–10.
PubMed
Google Scholar
Suzuki T, Uchida H, Takeuchi H, Tsuboi T, Hirano J, Mimura M. A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy. Hum Psychopharmacol. 2014;29:414–26. https://doi.org/10.1002/hup.2421.
Article
PubMed
Google Scholar
Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121–8.
Article
Google Scholar
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.
Article
Google Scholar
Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16:505–24.
PubMed
PubMed Central
Google Scholar
Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886–91. https://doi.org/10.1176/appi.ps.55.8.886.
Article
PubMed
Google Scholar
De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs. 2015;29:637–58. https://doi.org/10.1007/s40263-015-0269-4.
Article
CAS
PubMed
Google Scholar
Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74:957–65. https://doi.org/10.4088/JCP.13r08440.
Article
PubMed
Google Scholar
Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24. https://doi.org/10.4088/JCP.15032su1.
Article
PubMed
Google Scholar
Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, et al. Effectiveness of long-acting injectable vs Oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2017;44:603–19. https://doi.org/10.1093/schbul/sbx090.
Article
Google Scholar
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–9. https://doi.org/10.1124/jpet.102.033175.
Article
CAS
PubMed
Google Scholar
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400–11. https://doi.org/10.1038/sj.npp.1300203.
Article
CAS
PubMed
Google Scholar
de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41:674–86. https://doi.org/10.1093/schbul/sbv001.
Article
PubMed
PubMed Central
Google Scholar
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137–40.
Article
CAS
Google Scholar
Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology. 2007;190:373–82. https://doi.org/10.1007/s00213-006-0621-y.
Article
CAS
PubMed
Google Scholar
Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617–24. https://doi.org/10.4088/JCP.11m07530.
Article
CAS
PubMed
Google Scholar
Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205:135–44. https://doi.org/10.1192/bjp.bp.113.134213.
Article
PubMed
Google Scholar
Potkin SG, Preda A. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opin Pharmacother. 2016;17:395–407. https://doi.org/10.1517/14656566.2015.1114100.
Article
CAS
PubMed
Google Scholar
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
Article
Google Scholar
Guy W. ECDEU assessment manual for psychopharmacology - revised (DHEW Publ no ADM 76–338). Rockville: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
Google Scholar
Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168:498–504. https://doi.org/10.1016/j.schres.2015.07.007.
Article
PubMed
Google Scholar
McKeage K. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. CNS Drugs. 2014;28:171–83. https://doi.org/10.1007/s40263-013-0134-2.
Article
CAS
PubMed
Google Scholar
Calabrese JR, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a double-blind, placebo-controlled, randomized withdrawal study. J Affect Disord. 2018;241:425–32. https://doi.org/10.1016/j.jad.2018.06.043.
Article
CAS
PubMed
Google Scholar
Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus Oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther. 2018. https://doi.org/10.1007/s12325-018-0785-y.
Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148:117–21. https://doi.org/10.1016/j.schres.2013.05.016.
Article
PubMed
Google Scholar
Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19:3–5. https://doi.org/10.1017/S1092852913001016.
Article
PubMed
Google Scholar
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603–9. https://doi.org/10.1176/appi.ajp.2011.10081224.
Article
PubMed
Google Scholar
Ishigooka J, Nakamura J, Fujii Y, Iwata N, Kishimoto T, Iyo M, et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161:421–8. https://doi.org/10.1016/j.schres.2014.12.013.
Article
PubMed
Google Scholar
Correll CU, Kern Sliwa J, Najarian DM, Saklad SR. Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectr. 2018. In press.
Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–68. https://doi.org/10.2147/PPA.S124658.
Article
PubMed
PubMed Central
Google Scholar
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46 quiz 47.
PubMed
Google Scholar
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192–213. https://doi.org/10.1093/schbul/sbs150.
Article
PubMed
Google Scholar
Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568–75. https://doi.org/10.4088/JCP.12r08167.
Article
CAS
PubMed
Google Scholar
Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37–41. https://doi.org/10.1016/j.jclinepi.2013.01.012.
Article
PubMed
PubMed Central
Google Scholar
Schöttle D, Schimmelmann BG, Ruppelt F, Bussopulos A, Frieling M, Nika E, et al. Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia-spectrum and bipolar I disorders: four-year follow-up of the ACCESS II study. PLoS One. 2018;13:e0192929. https://doi.org/10.1371/journal.pone.0192929.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schöttle D, Schimmelmann BG, Karow A, Ruppelt F, Sauerbier A-L, Bussopulos A, et al. Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia spectrum and bipolar I disorders: the 24-month follow-up ACCESS II study. J Clin Psychiatry. 2014;75:1371–9. https://doi.org/10.4088/JCP.13m08817.
Article
PubMed
Google Scholar
Fleischhacker WW, Baker RA, Eramo A, Sanchez R, Tsai L-F, Peters-Strickland T, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophr Res. 2014;159:415–20. https://doi.org/10.1016/j.schres.2014.09.019.
Article
PubMed
Google Scholar
Schreiner A, Svensson A, Wapenaar R, Cherubin P, Princet P, Serazetdinova L, et al. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). World J Biol Psychiatry. 2014;15:534–45. https://doi.org/10.3109/15622975.2014.902990.
Article
PubMed
Google Scholar
Peters-Strickland T, Zhao C, Perry PP, Eramo A, Salzman PM, McQuade RD, et al. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr. 2016;21:1–6. https://doi.org/10.1017/S1092852916000365.
Article
Google Scholar
Meduri M, Gregoraci G, Baglivo V, Balestrieri M, Isola M, Brambilla P. A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. J Affect Disord. 2016;191:187–208. https://doi.org/10.1016/j.jad.2015.11.033.
Article
CAS
PubMed
Google Scholar
Atar D, Ong S, Lansberg PJ. Expanding the evidence base: comparing randomized controlled trials and observational studies of statins. Am J Ther. 2015;22:e141–50. https://doi.org/10.1097/MJT.0b013e318245ce94.
Article
PubMed
Google Scholar
Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29:113–30. https://doi.org/10.1007/s40263-015-0230-6.
Article
CAS
PubMed
Google Scholar
Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011;8:e1001026. https://doi.org/10.1371/journal.pmed.1001026.
Article
PubMed
PubMed Central
Google Scholar
Ahrén B, Mathieu C, Bader G, Schweizer A, Foley JE. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 2014;57:1304–7. https://doi.org/10.1007/s00125-014-3222-z.
Article
CAS
PubMed
Google Scholar
Naudet F, Maria AS, Falissard B. Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One. 2011;6:e20811. https://doi.org/10.1371/journal.pone.0020811.
Article
CAS
PubMed
PubMed Central
Google Scholar
Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine. 2004;22:3214–24. https://doi.org/10.1016/j.vaccine.2003.08.050.
Article
CAS
PubMed
Google Scholar
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–92. https://doi.org/10.1056/NEJM200006223422507.
Article
CAS
PubMed
PubMed Central
Google Scholar
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–86. https://doi.org/10.1056/NEJM200006223422506.
Article
CAS
PubMed
Google Scholar
Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Res Clin Pract. 2010;88(Suppl 1):S3–9. https://doi.org/10.1016/S0168-8227(10)70002-4.
Article
PubMed
Google Scholar